A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole

Trial Profile

A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Amoxicillin (Primary) ; Clarithromycin (Primary) ; Tripotassium dicitratobismuthate (Primary) ; Vonoprazan (Primary) ; Lansoprazole
  • Indications Helicobacter pylori infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 19 Jul 2017 Status changed from recruiting to completed.
    • 18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.
    • 18 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top